Royce & Associates LP Sells 10,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Royce & Associates LP reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,000 shares of the biopharmaceutical company's stock after selling 10,000 shares during the quarter. Royce & Associates LP's holdings in Gilead Sciences were worth $6,466,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Gilead Sciences by 6.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 111,772 shares of the biopharmaceutical company's stock worth $10,324,000 after purchasing an additional 6,815 shares during the last quarter. Choate Investment Advisors lifted its position in Gilead Sciences by 3.8% during the 4th quarter. Choate Investment Advisors now owns 9,722 shares of the biopharmaceutical company's stock worth $898,000 after buying an additional 353 shares in the last quarter. Globeflex Capital L P grew its holdings in Gilead Sciences by 90.2% during the 4th quarter. Globeflex Capital L P now owns 404,605 shares of the biopharmaceutical company's stock worth $37,373,000 after acquiring an additional 191,901 shares during the last quarter. Natixis Advisors LLC increased its position in Gilead Sciences by 97.6% in the 4th quarter. Natixis Advisors LLC now owns 334,737 shares of the biopharmaceutical company's stock valued at $30,920,000 after acquiring an additional 165,374 shares in the last quarter. Finally, Frank Rimerman Advisors LLC raised its stake in shares of Gilead Sciences by 0.7% in the fourth quarter. Frank Rimerman Advisors LLC now owns 32,318 shares of the biopharmaceutical company's stock worth $2,985,000 after acquiring an additional 232 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 302,785 shares of company stock valued at $30,503,250 in the last three months. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.1 %

GILD stock traded up $1.21 during trading hours on Friday, reaching $107.08. 26,496,292 shares of the stock were exchanged, compared to its average volume of 6,797,069. The company has a market cap of $133.35 billion, a price-to-earnings ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The firm's 50-day moving average is $103.68 and its 200-day moving average is $93.75. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

Several research firms have recently commented on GILD. Bank of America increased their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Morgan Stanley lifted their price objective on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.